Early clinical experience with IPX203 in Parkinson's disease with motor fluctuations

Motor fluctuations remain a major challenge in the treatment of Parkinson's disease (PD). IPX203 is a novel extended-release formulation of levodopa/carbidopa designed to provide rapid onset of benefit while maintaining therapeutic levodopa concentrations for a longer duration than immediate-release formulations. This review summarizes the formulation, pharmacokinetic profile, and clinical efficacy of IPX203 and discusses early clinical experience following its introduction into routine practice in the United States. Phase 2 studies demonstrated rapid levodopa absorption and prolonged plasma exposure, while the phase 3 RISE-PD trial showed significantly greater Good ON time with fewer daily doses compared with optimized immediate-release levodopa/carbidopa. The unique formulation combines immediate-release granules with mucoadhesive extended-release pellets that prolong levodopa delivery within the proximal small intestine. Early clinical experience suggests that many patients achieve meaningful improvements in motor fluctuations, treatment convenience, and overnight symptom control following conversion to IPX203. Three representative patient vignettes illustrate common clinical scenarios and practical approaches to treatment optimization. IPX203 provides a novel oral levodopa/carbidopa delivery strategy that combines rapid onset with prolonged duration of benefit. Clinical trial data and early clinical experience support its use as an effective option for patients with PD experiencing motor fluctuations and highlight the importance of individualized treatment optimization to maximize therapeutic benefit.